- Home
- NPV vs KROS Comparison
NPV vs KROS Comparison
Compare NPV & KROS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NPV | KROS |
|---|---|---|
| Founded | 1993 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 223.2M | 206.0M |
| IPO Year | 1995 | 2020 |
Fundamental Metrics
Financial Performance| Metric | NPV | KROS |
|---|---|---|
| Price | $9.76 | $11.17 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $21.86 |
| AVG Volume (30 Days) | 120.0K | ★ 159.9K |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | ★ 3.90% | N/A |
| EPS Growth | N/A | ★ 146.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $243,864,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2,751.79 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.68 | $9.69 |
| 52 Week High | $11.81 | $22.55 |
Technical Indicators
Market Signals| Indicator | NPV | KROS |
|---|---|---|
| Relative Strength Index (RSI) | 21.50 | 52.28 |
| Support Level | N/A | $10.57 |
| Resistance Level | $11.61 | $11.61 |
| Average True Range (ATR) | 0.12 | 0.41 |
| MACD | -0.03 | -0.02 |
| Stochastic Oscillator | 7.27 | 42.86 |
Price Performance
Historical ComparisonAbout NPV Nuveen Virginia Quality Municipal Income Fund
Nuveen Virginia Quality Municipal Income Fund is a diversified closed-end management investment company. The fund seeks to provide current income exempt from both regular federal and designated state income taxes. The fund invests in a portfolio of municipal obligations issued by state and local government authorities. Company mostly invest in Education and Civic Organizations, Tax Obligation/General, Healthcare, Utilities , Housing/Multifamily, Transportation, and Others.
About KROS Keros Therapeutics Inc.
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.